Barbara Klencke insider trades
Open-market stock purchases and sales by Barbara Klencke, Director at Xencor Inc, from SEC Form 4 filings since Mar 8, 2016.
Track record: 0% of 4 scored buys are up 5% or more since purchase, averaging -82%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 16, 2026 | XNCR Xencor Inc | Bought (not open market) | — |
| Jun 16, 2026 | XNCR Xencor Inc | Bought (not open market) | — |
| May 20, 2026 | TCRX TScan Therapeutics, Inc | Bought (not open market) | — |
| Apr 16, 2026 | ALXO ALX Oncology Holdings Inc | Bought (not open market) | — |
| Mar 3, 2026 | ALXO ALX Oncology Holdings Inc | Bought (not open market) | — |
Companies traded
- XNCR Xencor Inc: other filings, last Jun 16, 2026
- TCRX TScan Therapeutics, Inc: 4 buys, last May 20, 2026
- ALXO ALX Oncology Holdings Inc: other filings, last Apr 16, 2026
- EFTR eFFECTOR Therapeutics, Inc: other filings, last Jun 13, 2024
- SRRA Sierra Oncology, Inc: 5 buys, last Jul 1, 2022
- DNAI ProNAi Therapeutics Inc: other filings, last Sep 30, 2016